Journal
WORLD JOURNAL OF SURGICAL ONCOLOGY
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12957-022-02591-5
Keywords
Stage IB gastric cancer; Chemotherapy; Competing risk analysis
Funding
- Science and Technology Program of traditional Chinese Medicine in Zhejiang Province [2021ZB208]
- Zhejiang Medical and Health Science and Technology Plan Project [2021KY927]
Ask authors/readers for more resources
According to the competing risk analysis, adjuvant chemotherapy benefits patients with stage IB gastric adenocarcinoma by reducing the cumulative incidence of cancer-specific death (CSD).
Background This study aimed to investigate the potential effect of adjuvant chemotherapy in patients diagnosed with stage IB gastric adenocarcinoma (GAC). Method A total of 1727 patients were included in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 and divided into the chemotherapy and no-chemotherapy groups. Then, the methods of Kaplan-Meier analysis, propensity score matching (PSM), and competing risk analysis were implemented. Results After PSM, no significant difference was found in the chemotherapy and no-chemotherapy groups in overall survival (OS) (p=0.4) and cancer-specific survival (CSS) (p=0.12) in survival curves. The competing risk analysis presented that the 5-year cumulative incidence of cancer-specific death (CSD) was significantly lower in patients receiving chemotherapy (11.5% vs. 20.8%, p=0.007), while no significant discrepancy was observed in other causes of death (OCD) in both groups (10.6% vs. 10.9%, p=0.474). Multivariable competing risks regression models presented a significant correlation between chemotherapy and CSD (HR, 0.51; 95%CI, 0.31-0.82; p=0.007). Conclusion The stage IB GAC patients can benefit from adjuvant chemotherapy based on this competing risk analysis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available